Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share new research and clinical trial findings at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, including studies on new treatment approaches for prostate, bile duct and head and neck cancers, personalized radiation therapy based on genetic risk, and advances in targeted radiation and radioligand therapy designed to improve cancer control while limiting treatment side effects. 

In addition to the nine studies that will be featured in news briefings at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, the following studies on advances in radiation medicine and cancer care were recommended by ASTRO experts as highlights for news professionals.

University of Cincinnati hematology researcher Jahnavi Gollamudi, MD, has received new grant funding to study how inflammation predicts bone complications in people with sickle cell disease, offering new hope for treatment.

About the Study: Results of this study suggest that substitution effects are possible between obesity-labeled and diabetes-labeled GLP-1 RAs, varying by state coverage policies, that could impact coverage decisions.

About the Study: In this randomized clinical trial, CT-155 improved motivation and pleasure negative symptoms with a small-to-moderate effect size comparable with psychosocial interventions and pharmacologic treatment in psychiatry and was well tolerated and safe, thus representing a novel adjunctive therapy for schizophrenia. CT-155 may represent a scalable, accessible option for improving schizophrenia negative symptoms.

Researchers at Mayo Clinic have designed an artificial intelligence model that can potentially predict an individual’s risk of developing pancreatic cancer years before diagnosis.